Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Arrowhead Publishers | The Global Antibacterials Market R&D Pipelines Market Analysis and Competitive Landscape

The Global Antibacterials Market R&D Pipelines Market Analysis and Competitive Landscape

The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.

This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.

The following product classes are analyzed in this report:

* aminoglycosides

* carbapenems

* cephalosporins

* dihydrofolate reductase inhibitors

* glycopeptides

* ketolides

* lipopeptides

* macrolides

* penicillins

* oxazolidinones

* pleuromutulins

* quinolones

The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.

The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.

Key Features of this report:

* Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.

* In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.

* Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.

* Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.

* Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.

Published: August 28, 2007

Pages: 126

PDF Format
Table of Contents

Price

Single User PDF $2499.00

Corporate Wide Licence PDF $5499.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions